Vela Diagnostics, a turnkey manufacturer for IVD NGS and PCR workflow solutions announces its 2016 results and highlights
Singapore (January 31, 2017) – Vela Diagnostics announced today that it reports a triple revenue growth in FY16. This is mainly driven by market outreach expansion, innovation, new customer acquisitions and an expansion in sales coverage across the globe.
Vela Diagnostics is proud to highlight the launch of the Sentosa Next-Generation Sequencing (NGS) workflow, the attainment of regulatory approvals and successful completion of corporate development activities.
In the space of regulatory approvals in the 2016 - the following milestones were achieved. In May and June 2016, the NGS-based Sentosa SQ HCV Genotyping Assay, which includes drug resistance detection, was approved by the Australian Therapeutic Goods Administration (TGA) for in-vitro diagnostic use and received the European CE mark for in-vitro diagnostic use respectively. Currently, Vela Diagnostics is the only company in the market, providing an end-to-end NGS-based IVD oncology workflow with various regulatory approvals for NSCLC and CRC.
In September 2016, the Sentosa SA ZIKV RT-PCR Test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for zika virus detection.
From the corporate development perspective Vela Diagnostics has completed the acquisition of LifeCode Inc; and a full transition into the Vela Diagnostics portfolio under the name of Vela Genomics has been completed. Vela Genomics is a clinical interpretation reporting service that provides clinicians with a complete Patient-to-Treatments matching solution, therefore empowering clinicians with information on available treatment options and up-to-date relevant clinical trials.
Vela Diagnostics aims to accelerate the adoption of Next-Generation Sequencing (NGS) in routine clinical diagnostics.